In K562 cell variants, imatinib resistance was associated with low levels of BCR-ABL and its tyrosine kinase activity (a phenomenon also detected in chemoresistant CML patients). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.